Our Spirulina bioactive peptide ingredient is designed for food and nutrition applications that call for a mild flavor, low color, and good clarity. Our product materials describe enzymatic hydrolysis, fractionation, enrichment, and decolorization/deodorization as steps in making this small-peptide ingredient. Here we introduce our product specifications and quality practices, review the relevant research, and explain what still requires product-specific validation.
1. What is our Spirulina bioactive peptide ingredient?
We developed our ingredient to address some formulation challenges associated with conventional Spirulina powder, such as dark-green color, marine odor, sedimentation, and limited solubility in certain systems. Our target applications include clear beverages, functional drink mixes, sports nutrition products, nutritional drops, and capsules. These are development directions; final performance depends on the finished formula and processing conditions.
Our specification requires at least 90% of the peptide fraction to be below 1,000 Da; cited batch results range from 97.1% to 99.0%. We also specify protein at no less than 78 g per 100 g, total amino acids at about 81 g per 100 g, essential amino acids at no less than 31.7 g per 100 g, branched-chain amino acids at no less than 17.3 g per 100 g (about 20.2 g per 100 g in the cited batch data), and dietary fiber at no less than 8 g per 100 g.
The molecular-weight distribution shows the size of peptide fractions in our ingredient. It does not, by itself, establish absorption, bioavailability, a clinical benefit, or a specific sensory result; those outcomes require appropriate testing of finished products.
2. How do we describe our quality controls and supply?
Our product materials describe a testing program that evaluates molecular-weight distribution by HPLC-SEC, peptide content through OPA/TNBS or LC-MS methods, and amino-acid composition through amino-acid analysis. We also describe batch checks for color, odor, solubility, clarity, and consistency. Our listed safety specifications include lead at no more than 0.5 mg/kg, total arsenic at no more than 1.0 mg/kg, cadmium at no more than 0.2 mg/kg, and a total plate count at no more than 10,000 CFU/g; Salmonella and Staphylococcus aureus are listed as not detected in 25 g. Our materials also state that we monitor microcystins.
Buyers evaluating a specific lot should request its current certificate of analysis, method and validation details, relevant third-party results, traceability records, storage conditions, and complete stability documentation. Our materials mention a 24-month stability program; any shelf-life conclusion should be tied to the available data, packaging, and storage conditions.
We report a vertically coordinated supply chain that includes about 7,000 mu of cultivation area, five bases, annual capacity at the 10,000-ton scale, and exports to more than 30 countries or regions. These figures describe our operations; buyers can assess them through qualification, audit, and delivery records. Our materials also list two patent applications filed on August 5, 2026, concerning peptide preparation and a transparent beverage. They are applications, not granted patents; current status should be checked in the relevant patent register.
3. What does published research say about Spirulina and our peptide?
Our product materials discuss studies of Spirulina and related peptides, including lipid, blood-pressure, body-composition, and inflammation outcomes. The lipid figures sometimes quoted together come from separate meta-analyses, so we keep their sample sizes and effect measures distinct: A 2023 meta-analysis of 20 studies and 1,076 participants reported standardized mean differences for lipid outcomes. A separate 2015 meta-analysis of seven randomized trials reported changes in mg/dL, including total cholesterol and LDL cholesterol. Their study counts and effect measures should not be merged into a single result.
A 2021 blood-pressure meta-analysis included five trials and 230 participants. A 2019 meta-analysis of Spirulina and obesity-related outcomes included five studies. We view these reviews as signals for further study; the underlying trials differ in participants, Spirulina preparations, doses, duration, and methods.
Our product materials identify the seven-amino-acid sequence TMEPGKP (759 Da) as a peptide fingerprint and cite angiotensin-converting enzyme (ACE) inhibition. The original research on this peptide reported laboratory findings, including work in cultured endothelial cells; it does not establish a blood-pressure benefit in people or clinical validation of our finished product. Most human research discussed in our materials involved whole Spirulina powder, not this specific small-peptide formulation. Our materials do not establish product-specific randomized human trials.
We distinguish research on whole Spirulina from evidence for our specific peptide product. Laboratory mechanisms such as Nrf2-related antioxidant activity and NF-κB-related inflammatory signaling are research findings, not proven treatment effects. We see clear beverages, powders, and nutrition formats as potential development areas; any health-related positioning requires product-specific evidence and review for the relevant market. Topical cosmetic use requires a separate assessment.
Takeaway: Our Spirulina bioactive peptide ingredient is designed for clearer, milder-tasting formulations. We report product specifications and development opportunities; buyers should validate lot-specific quality data, supply capacity, and stability documentation. We distinguish whole-Spirulina studies from research on our specific peptide product and do not treat early findings as proof of disease prevention or treatment.